

**Table S2. Chemotherapy and CD19 mAb treatment**

No.	Treatment before 1 <sup>st</sup> mAb application	Days between pretreatment and start of mAb	Bone marrow status prior to mAb treatment	MRD prior to mAb	MRD post mAb	Lowest MRD level after 1 <sup>st</sup> mAb	Additional HSCT after 1 <sup>st</sup> mAb	Additional HSCT after mAb response	MRD prior to last HSCT	MRD post last HSCT
1	clofarabine, cyclophosphamide, etoposide	53	M1, MRD	5,00E-03	negative	negative	Yes	Yes	5,00E-03	negative
2	haploidentical HSCT with myeloablative conditioning	22	M1, MRD	1,00E-06	negative	negative	No	No	1,00E+00	1,00E-06
3	clofarabine, cyclophosphamide, etoposide	23	M1, MRD	1,00E-03	negative	negative	Yes	Yes	5,00E-05	5,00E-03
4	MSD HSCT with myeloablative conditioning	461	M1, MRD	5,00E-03	5,00E-05	5,00E-06	Yes	Yes	5,00E-04	5,00E-04
5	vincristine and bortezomib i.v., methotrexate i.th.	38	M1, MRD	3,00E-04	negative	negative	Yes	Yes	5,00E-05	negative
6	daunorubicin, bortezomib	7	M1, MRD	7,00E-04	1,00E-06	5,00E-06	Yes	No	1,00E-06	negative
7	fludarabine, daunorubicin * cytarabine, melphalan	45, * 32	M2 * M1, MRD	1,50E-01 * 1,10E-02	1,50E-01 * 1,10E-06	1,10E-06	Yes	No	1,00E+00	1,10E-02
8	imatinib, ongoing	0	M1, MRD	3,00E-03	negative	negative	Yes	Yes	1,00E-04	negative
9	dasatinib, ongoing	0	M1, MRD	8,40E-04	negative	negative	Yes	Yes	negative	negative
10	haploidentical HSCT with myeloablative conditioning	13	M1, MRD	1,00E-03	negative	negative	No	Yes	4,00E-02	1,00E-03
11	clofarabine, cyclophosphamide, etoposide	28	M1, MRD	1,41E-02	9,30E-03	negative	Yes	not applicable	1,00E-06	1,00E-06
12	daunorubicin, fludarabine, cytarabine and G-CSF	43	M1, MRD	1,00E-06	1,00E-04	negative	Yes	not applicable	1,00E-04	negative
13	cytarabine, etoposide	28	M1, MRD	5,00E-04	5,00E-04	negative	Yes	not applicable	5,00E-04	5,00E-04
14	clofarabine, cyclophosphamide, etoposide	32	M1, MRD	5,00E-04	5,00E-03	5,00E-06	Yes	not applicable	5,00E-03	5,00E-06

In patient #7 \* indicates the second attempt of treatment after additional cytoreductive chemotherapy with cytarabine and melphalan.

All corresponding data is indicated. Minimal residual disease (MRD) was defined negative, if below qualitative detection threshold.

Monoclonal antibody (mAb). Hematopoietic stem cell transplantation (HSCT). Bone marrow status was defined according to M1 <

5% blasts, M2 5-25% blasts, M3 > 25% blasts [49].

1. Raetz, EA, Borowitz, MJ, Devidas, M, Linda, SB, Hunger, SP, Winick, NJ, et al. (2008). Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol **26**: 3971-3978.